Pemetrexed in Advanced NSCLC: A Review of the Clinical Data
Pemetrexed in Advanced NSCLC: A Review of the Clinical Data
Lung cancer is the leading cause
of cancer death in both men
and women in the United States,
with an estimated 173,770 new cases
and 160,440 deaths in 2004. Eighty
percent of lung cancers are non-smallcell
lung cancer (NSCLC). More people
die from lung cancer than from
breast, prostate, and colon cancer combined,
despite advances in the control
of local disease. This is partly because
one-third of patients with lung
cancer present with metastatic disease,
but also because most patients with
stage III and as many as 50% with
early-stage disease relapse after definitive
A large meta-analysis in 1995
showed a 10% increase in 1-year survival
rate and an improvement of 1.5
months in median overall survival for
cisplatin-containing regimens in advanced
NSCLC. In the late 1990s,
third-generation agents including paclitaxel,
docetaxel (Taxotere), gemcitabine
(Gemzar), irinotecan (Camptosar), and
vinorelbine (Navelbine) have been extensively
studied. Combined with platinum
agents, these form the standard
of care for newly diagnosed advanced
NSCLC. They produce response rates
of 10% to 20% in previously untreated
patients as single agents[4-7] and
in combination with platinum, 20%
to 40% response and median survival
of 8 to 11 months in phase III trials.[
8-13] However, these gains in survival
have been rather modest.
Moreover, there is no clearly demonstrated
superiority of one of these
modern platinum doublets over another.[
Chemotherapy, in particular docetaxel,
offers a survival advantage as
second-line therapy as well.[19,20]
Gefitinib (Iressa) is indicated for use
in patients whose tumors have progressed
after both platinum- and docetaxel-
Pemetrexed (Alimta) has more recently
been introduced into clinical
study. It has activity in multiple
cancer types and is a novel antimetabolite.[
24] On the basis of showing
a survival advantage in combination
with cisplatin as compared to singleagent
cisplatin in mesothelioma, pemetrexed
was approved for use in
mesothelioma by the US Food and
Drug Administration (FDA). As a single agent in the treatment of second-
line NSCLC, it showed equal efficacy
with improved tolerability
compared with docetaxel in a phase
III study. There are also data from
phase II platinum/pemetrexed doublet
studies showing efficacy comparable
to best historical controls but with
very promising toxicity profiles (Table
1). This article will focus on pemetrexed
in the treatment of advanced
Pemetrexed interferes with at least
three enzymes in pyrimidine and purine
biosynthesis, thymidylate synthase,
dihydrofolate reductase, and
glycinamide ribonucleotide formyltransferase
(Figure 1). A retrospective
analysis of severe adverse
events and their relationship to elevated
plasma homocysteine (a surrogate
for folate nutritional status) and
methylmelonic acid (a surrogate for
vitamin B12 status) levels was performed
during the early clinical development
Elevated plasma homocysteine and
methylmelonic acid levels, indicating
folate and B12 deficiency, were associated
with a statistically significantly
greater risk of neutropenia, thrombocytopenia,
such as infection, mucositis, and diarrhea,
In December 1999, all patients being
treated with pemetrexed began
receiving folic acid to reduce homocysteine
and vitamin B12 to reduce
methylmelonic acid. This intervention
has since been shown to reduce homocysteine
and methylmelonic acid
plasma levels, and patients who received
supplementation in this way
experienced significantly fewer toxicities.[
33] This was shown quite
clearly through the phase III malignant
pleural mesothelioma trial, where
there was a clear improvement in the
tolerability profile without a compromise
in response or survival with the
initiation of mandatory vitamin supplementation
part of the way through
the trial (Table 2).
Clinical Trials Data
With and Without Vitamin
Supplementation: Phase I Trials
Multiple schedules of single agent pemetrexed have been evaluated in phase I trials, including a daily * 5 schedule every 3 weeks, weekly for 4 weeks every 4 weeks, and once every 3 weeks. The schedule of pemetrexed administered once every 3 weeks as a 10-minute intravenous bolus has been studied most extensively. In one study, 37 patients received doses ranging from 50 to 700 mg/m2 every 3 weeks. However, neither folate nor vitamin B12 supplementation was offered and side effects at the 700 mg/m2 dose level were significant. Neutropenia, thrombocytopenia,mucositis, fatigue, diarrhea, rash, and/or anorexia were dose-limiting. Side effects including grade 3 neutropenia, thrombocytopenia, and cumulative asthenia were experienced at the preceding dose level of 600 mg/m2, and this dose was considered an acceptable one for further phase II trials. There was activity against advanced pancreatic cancer and colorectal cancer on this every-3-week schedule. Hammond evaluated pemetrexed as a 10-minute intravenous bolus every 3 weeks at a starting dose of 600 mg/m2 plus oral folic acid in patients who had had prior treatment in another phase I trial. Doses ranged from 600 to 1,400 mg/m2 in 70 patients, all with prior chemotherapy. Neutropenia, anemia, and thrombocytopenia (more severe in the heavily pretreated patients), as well as nonhematologic side effects of rash, asthenia, pedal edema, and decline in creatinine clearance, have been observed. Less toxicity was observed with vitamin supplementation. More over, even at doses as high as 1,200 mg/m2, none of these toxicities were dose-limiting. There was a partial response in one patient with metastatic colon cancer. Single-Agent Pemetexed Without Vitamin Supplementation: Phase II Studies
Two phase II single-agent studies of pemetrexed were conducted in previously untreated patients with NSCLC before the vitamin supplementation requirement: one in Canada and the other in Australia and South Africa. Prophylactic dexamethasone was not uniformly used in either study. The study done in Canada enrolled 33 patients. The starting pemetrexed dose was reduced from 600 to 500 mg/m2 once every 21 days after three patients had enrolled, because of excessive toxicities in these patients. Grade 3/4 hematologic toxicities were as follows: neutropenia, 39%; febrile neutropenia, 12%; anemia, 9%; and thrombocytopenia, 3%. Grade 3 nonhematologic toxicities (there were no grade 4 toxicities) were 39% for skin rash and 27% for fatigue. The incidences of anorexia, nausea, vomiting, diarrhea, and increased bilirubin or aspartate aminotransferase (AST) levels were all 9% to 12%. Grade 3 skin rash was seen in 47.5% of patients not treated with dexamethasone and 12% of patients who received dexamethasone prophylaxis. Response rate was 23.3%, median overall survival was 9.6 months, and the 1-year survival rate was 25.3%. The study authored by Clarke et al done in Australia and South Africa used 600 mg/m2 of pemetrexed once every 21 days throughout the study. A total of 59 patients received therapy. Response rate was 15.8%, median time to progression was 4.4 months, median survival was 7.2 months, and the 1-year survival rate was 32%. Grade 3/4 hematologic toxicities included neutropenia (42%), anemia (10%), and thrombocytopenia (5%), and grade 3/4 nonhematologic toxicities were skin rash (31%) that improved after dexamethasone prophylaxis was introduced, fatigue (5%), nausea (14%), vomiting (9%), infection/fever (5%), diarrhea (3%), and stomatitis (5%). Grade 3/4 asymptomatic reversible hepatic enzyme elevation, which was seen in 24% of patients, did not require dose reduction or delay (see Tables 3 and 4).[25,26,34-42] Single-Agent Pemetrexed in Previously Treated Patients With and Without Vitamin Supplementation: Phase II and III Studies
There have been two studies of single-agent pemetrexed for previously treated NSCLC: a phase II singlearm study by Smit et al and a phase III study comparing pemetrexed with docetaxel reported by Hanna et al. In both studies pemetrexed was dosed at 500 mg/m2 every 21 days. The phase II study did not include vitamin supplementation; the phase III study did. In both studies, all patients received premedication with dexamethasone to reduce rash. Of 81 advanced NSCLC patients who progressed within 3 months of their last chemotherapy in the phase II study, the response rate was 8.9%, median time to progression was 2 months, and median overall survival was 5.7 months. Grade 3/4 hematologic toxicities were neutropenia in 35% of patients, anemia in 13%, and thrombocytopenia in 15%; grade 3/4 nonhematologic toxicities were skin rash in 5%, lethargy in 5%, nausea in 1%, vomiting in 3%, aminotransferase level elevation in 6%, and alkaline phosphatase level elevation in 1%. There was greatly decreased skin toxicity with dexamethasone premedication even as compared with the studies mentioned earlier that did not routinely use dexamethasone. Four deaths on the study were possibly treatment related. In the study by Hanna et al, patients were randomized to receive pemetrexed at 500 mg/m2 (n = 283) or docetaxel at 75 mg/m2 (n = 288)once every 21 days. There were nearly overlapping response rates, times to progression, and median survival times (Table 4). However, on the pemetrexed arm, there was significantly less grade 3/4 neutropenia, febrile neutropenia, hospitalization for febrile neutropenia, hospitalization for adverse events, and alopecia, but significantly more transient elevation of alanine aminotransferase levels. Pemetrexed Plus Cisplatin Without Vitamin Supplementation
In a phase I trial by Thodtmann et al, pemetrexed at 500 mg/m2 and cisplatin at 75 mg/m2 were tolerated on a schedule of once every 21 days. It was conducted without vitamin supplementation but was premedicated with dexamethesone incidental to premedication of cisplatin. Responses were seen in patients with NSCLC, mesothelioma, colorectal cancer, and head and neck cancers. Neutropenia was the dose-limiting toxicity. Pemetrexed and cisplatin had no observed pharmacokinetic interaction. Two phase II studies in chemonaive NSCLC were conducted using pemetrexed at 500 mg/m2 plus cisplatin at 75 mg/m2 without vitamin premedication but with dexamethasone prophylaxis. Shepherd et al accrued 31 patients, with treatment resulting in a 46% response rate, a median survival of 8.9 months, and a 1-year survival rate of 49%. Hematologic toxicities (grade 3/4) were neutropenia in 35% of patients, febrile neutropenia in 3%, anemia in 19%, and thrombocytopenia in 3%. Nonhematologic toxicities (grade 3/4) were fatigue in 26%, nausea in 3%, vomiting in 3%, diarrhea in 10%, and stomatitis in 3%. The response rate was 39% with a median time to progression of 6.3 months and median overall survival of 10.9 months in the 36-patient study by Manegold et al. Hematologic toxicities (grade 3/4) were neutropenia in 59% of patients, anemia in 14%, and thrombocytopenia in 17%. Grade 3/4 nonhematologic toxicities were fatigue in 6% of patients, nausea/vomiting in 6%, diarrhea in 3%, and grade 3 bilirubin and AST level elevations in 3% each. The Shepherd and Manegold studies showed activity comparable to that of the most active regimens available. Pemetrexed Plus Carboplatin With Vitamin Supplementation
Two phase II studies of pemetrexed plus carboplatin completed accrual with preliminary data reported: one by Zinner et al and the other by Scagliotti et al. Encouraging activity seen in the Manegold and Shepherd studies, the prevalence of carboplatin-based therapy, together with preliminary data showing better tolerability of pemetrexed in lung cancer with vitamin use without loss of efficacy, encouraged an updated look at the efficacy and toxicity of pemetrexed/ platinum doublets in first-line advanced NSLC. Patients were treated with pemetrexed at 500 mg/m2 and carboplatin to an area under the concentration- time curve (AUC) of 6, with vitamin and dexamethasone prophylaxis in both studies. This regimen was based on data obtained from the phase I mesothelioma trial (no vitamin prophylaxis) by Hughes et al. In the study by Zinner et al, 50 patients were accrued with a response rate of 28.8% (49 patients evaluable for response). The median time to progression was 4.8 months, and with a minimum follow-up of 11 months, the median overall survival time is estimated at 13.5 months and the 1- year survival rate is estimated at 55.8%. Patients could elect to receive > 6 cycles if they had no disease progression, although at the start of the study the intended number was 6 cycles. The median number of chemotherapy cycles administered was 6 (range: 1 to > 15 cycles). Fifteen patients (30%) received ≥ 8 cycles (8 cycles, n = 6, 10 cycles, n = 2; 12 cycles, n = 4; 14 cycles, n = 2; 15 cycles, n = 1). Greater than 277 cycles were administered. Nonhematologic toxicity of grade ≥ 3 was experienced by three patients (6%); grade 3 diarrhea, neutropenic infection, and grade 3 fatigue all first occurred during the first six courses. Five patients had deep-vein thromboses or pulmonary emboli. Given the low rate of clotting in the multiple other single-agent and doublet pemetrexed studies, these are presumed not to be caused by this regimen. The absence of alopecia or neurosensory toxicities of grade > 1 is notable. Four patients had grade 4 hematologic toxicities (grade 3 toxicities not yet tabulated) first occurring during the first 6 courses, including one with neutropenia and two with anemia. In this randomized phase II study in previously untreated patients with advanced NSCLC reported by Scagliotti et al, patients were treated with either pemetrexed plus carboplatin exactly as in the study of Zinner et al or pemetrexed at 500 mg/m2 plus oxaliplatin (Eloxatin) at 120 mg/ m2 on day 1 of each 21-day cycle. Of 80 patients, 39 patients were randomized to pemetrexed/carboplatin and 41 to pemetrexed/oxaliplatin. The response rate, median time to progression, and estimated median overall survival on the pemetrexed/carboplatin arm were 31.6%, 4.5 months, and 9.9 months respectively. On the pemetrexed/ oxaliplatin arm, response rate, median time to progression, and estimated median overall survival were 26.8%, 4.9 months, and 9.3 months, respectively. Patients treated with pemetrexed/ carboplatin had grade 3/4 hematologic toxicities including neutropenia (26%), thrombocytopenia (18%), and anemia (8%). Grade 3/4 nonhematologic toxicities were fatigue (8%) and stomatitis (3%). On the pemetrexed/ oxaliplatin arm grade 3/4 hematologic toxicities were neutropenia (7%) thrombocytopenia (2%), and anemia (2%) and grade 3/4 nonhematologic toxicities were vomiting (7%), neuropathy (2%), diarrhea (2%), and hypersensitivity reactions (2%). Both these studies showed activity comparable to standard platinum doublets but with impressive tolerability, especially with pemetrexed plus carboplatin. The longer-than-expected survival seen in the study by Zinner et al may be accounted for by the large number of patients receiving at least second-line therapy upon progressing (76%), as compared to historical controls. The large number of cycles in 15 of the patients, at the very least, demonstrate impressive tolerability, though it is not clear from this study whether it offered benefit. Randomized trials are indicated. Pemetrexed Combinations With Nonplatinum Agents
There have been three phase II studies of pemetrexed-based nonplatinum regimens used to treat NSCLC reported. Two involved pemetrexed/ gemcitabine and the other pemetrexed/ vinorelbine. In one study by Monnerat et al, gemcitabine at 1,250 mg/m2 was given on days 1 and 8 with pemetrexed at 500 mg/m2 following gemcitabine on day 8 of a 21-day cycle. The administration of vitamins was introduced after 3 patients had completed treatment and while 10 patients were undergoing treatment, and all 60 patients received dexamethasone. The response, median progressionfree survival, median overall survival, and 1-year survival rate were 17%, 4.9 months, 11.3 months, and 44%, respectively. Grade 3/4 hematologic toxicities were neutropenia (63%), anemia (12%), and thrombocytopenia (5%). Febrile neutropenia occurred in 15% of patients. Grade 3 fatigue occurred in 23% of patients. There was an impressive survival, but a lower- than-expected response rate that may be ascribed to dose reductions and delays. To further explore this, a phase II by Adjei et al was done looking at alternative schedules of gemcitabine at 1,250 mg/m2 and pemetrexed at 500 mg/m2. None of the following three schedules were the same as in the Monnerat study: (A) pemetrexed followed by gemcitabine on day 1, gemcitabine on day 8; (B) gemcitabine followed by pemetrexed on day 1, gemcitabine on day 8; and (C) gemcitabine on day 1, pemetrexed followed by gemcitabine on day 8 (which was the schedule used in the earlier study). Schedule B was stopped early because of low response at interim analysis. Patients on arm A had less severe toxicity than patients on arm C with ≥ grade 3 events: 86% vs 93% (grade 4 events: 40% vs 50%). Response on arm A was 29%, thereby meeting the protocol-defined efficacy criteria, whereas arm C with partial response of 17% did not. The authors recommend schedule A (pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8) for further study. The second nonplatinum regimen used pemetrexed at 500 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on days 1 and 8 of a 21-day cycle with vitamin supplementation. Among the 34 patients, response was 35%. Survival data were not reported. Toxicities included grade 4 neutropenia (44%), febrile neutropenia (11%), and one treatment-related death. Twentyone percent of patients had grade 3/4 fatigue. This regimen has an activity similar to standard platinum doublets, but it may be more toxic than the carboplatin-containing regimen. Discussion Pemetrexed is approved by the FDA for use in combination with cisplatin in the treatment of malignant pleural mesothelioma; it was the first agent to show improved survival in this disease. In second-line NSCLC it was equally effective, but had superior tolerability compared to docetaxel in the largest second-line NSCLC phase III study yet reported.[ 26] In addition, it showed activity similar to historical controls formed by third-generation agents in multiple phase II studies of pemetrexed alone or in combination. The phase III mesothelioma trial showed that the addition of vitamin prophylaxis improved the tolerability without evident negative effects on activity. The combination of pemetrexed with carboplatin, cisplatin, or oxaliplatin is effective and safe, with activity comparable to any of the standard third-generation platinum doublet regimens. Phase II studies of pemetrexed/carboplatin with dexamethasone plus vitamins, in particular, showed powerful efficacy combined with a low incidence of grade 3/4 hematologic and nonhematologic toxicities. The excellent tolerability is apparent when compared to historical controls (Table 1). This suggests that this regimen may offer important improvements over standard regimens, a conclusion that would be consistent with the phase III single-agent second- line experience. This is reinforced by the observation that there was minimal toxicity of pemetrexed/carboplatin in multiple courses beyond 6 seen in the study by Zinner et al; however, whether courses beyond 4 or 6 offer any anticancer benefit will require other studies to determine. Pemetrexed is also a convenient regimen, requiring administration once every 21 days. Building on an earlier study looking at single-agent pemetrexed with folic acid, there are phase I studies under way evaluating pemetrexed at doses of > 500 mg/m2 in combination with both folate and vitamin B12, given the increased tolerability without decrease in efficacy observed with such prophylaxis in other studies. Combinations of nonplatinum agents with gemcitabine and vinorelbine in phase II studies have shown activity similar to that of standard platinum- containing doublets but without improvement in the toxicity profile. A recent presentation of results from a study of three dosing schemes showed best tolerability and activity with pemetrexed followed by gemcitabine on day 1, gemcitabine on day 8, a schedule that was both more active and less toxic than the pemetrexed plus gemcitabine schedule evaluated in an earlier study. Further study will be required to clarify the activity and tolerability. Given the efficacy and minimal severe and long-lasting toxicities (notably neurotoxicity) of pemetrexed in combination with platinum agents, these regimens should be studied as part of multimodality therapy in earlier- stage disease. In the case of surgery, such considerations are of increased relevance given data presented at the annual meetings of the American Society of Clinical Oncology in 2003 and 2004 showing clear and substantial reduction in the hazard ratio in those receiving standard platinum-containing doublets as adjuvant therapy.[47-49] Indeed, given its excellent tolerability, pemetrexed regimens may enable better compliance as postsurgical adjuvant therapy, a condition critical to providing a best chance at eradicating microscopic postsurgical disease. Pemetrexed is being studied in combination with radiation because there is preclinical evidence that it is a radiosensitizer. Full therapeutic doses of pemetrexed can be combined with therapeutic doses of chest radiation therapy as shown in a phase I dose-escalation study presented by Vokes et al. Pemetrexed plus carboplatin is being dose-escalated concurrently with chest radiation in another study that is presently under way. It is also an attractive candidate for combination with other new agents given excellent efficacy and tolerability. Thus, in addition to combining it with other modalities, pemetrexedbased treatment should be considered as a chemotherapy platform upon which to add novel therapy. Randomized trials comparing pemetrexed doublets to other doublets are also indicated.
2. Surveillance, Epidemiology, and End Results Program, 1973-1999. Bethesda, Md: Division of Cancer Control and Population Sciences, National Cancer Institute, 2002.
3. Non-small cell lung cancer collaborative group: chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995.
4. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapynaive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145-157, 2000.
5. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074-1780, 2000.
6. Gridelli C: The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small-cell lung cancer-Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6(suppl 1):4-7, 2001.
7. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer— a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447-453, 2000.
8. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-smallcell lung cancer. Br J Cancer 88:335-341, 2003.
9. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122-130, 2000.
10. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998.
11. Le Chevalier T, Brisgand D, Soria JC, et al: Long-term analysis of survival in the European randomized trial comparing vinorelbine/ cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(suppl 1):8-11, 2001.
12. Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol16:2133-2141, 1998.
13. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Study Group. J Clin Oncol 22:254-261, 2004.
14. Smit EF, Van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin- based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol 21:3909-3917, 2003.
15. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002.
16. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multicenter, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced nonsmall-cell lung cancer: The TAX326 study group. J Clin Oncol 21:3016-3024, 2003.
17. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus.carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001.
18. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
19. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354- 2362, 2000.
20. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000.
21. Fukuoka M, Yano S, Giaccone G, et al: Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003.
22. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003.
23. Zinner RG, Herbst RS,Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clin Lung Cancer April:5 (suppl 2):S67-S74, 2004.
24. Adjei AA: Pemetrexed (Alimta): A novel multitargeted antifolate agent. Expert Rev AnticancerTher 3:145-156, 2003.
25. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636- 2644, 2003.
26. Hanna NH, Shepherd FA, Rosell R, et al: A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy (abstract 2503). Proc Am Soc Clin Oncol 22:622, 2003.
27. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997.
28. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545- 552, 2002.
29. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite (abstract 300). Proc Am Soc Oncol 20:76a, 2001.
30. McDonald AC, Vasey PA, Adams L, et al: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4:605-610, 1998.
31. Rinaldi DA, Burris HA, Dorr FA, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995.
32. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of the multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380, 1999.
33. Hammond L, Baker SD, Villalona- Calero SG, et al: A phase I and pharmacokinetic study of the multitargeted antifol (MTA) LY231514 with folic acid (abstract). Ann Oncol 9:620, 1998.
34. Rusthoven JJ, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17:1194-1199, 1999.
35. Clarke SJ, Abratt R, Goedhals L, et al: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13:737-741, 2002.
36. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as firstline therapy in patients with advanced nonsmall cell lung carcinoma. Cancer 92:595-600, 2001.
37. Manegold C, Gatzemeier U, von Pawel J, et al: Front-line treatment of advanced nonsmall-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000.
38. Zinner R, Obasaju CK, Fossella FV, et al: Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): A phase II trial (abstract 7074). Proc Am Soc Clin Oncol 23:631, 2004.
39. Scagliotti G, Kortsik C, Castellano D, et al: Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (abstract 2513). Proc Am Soc Clin Oncol 22:625, 2003.
40. Monnerat C, LeChevalier T, Novello S, et al: Clinical results from a phase II trial of pemetrexed + gemcitabine in advanced nonsmall cell lung cancer (abstract 483PD). Ann Oncol 13(suppl 5):132, 2002.
41. Adjei A, Nair S, Reuter N, et al: Pemetrexed (Pem)/gemcitabine (Gem) as frontline therapy for advanced NSCLC: A randomized, phase II trial of three schedules (abstract 7070). Proc Am Soc Clin Oncol 23:630, 2004.
42. Clarke S, Underhill C, White S, et al: Phase II study of pemetrexed and vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer (abstract #546P). Ann Oncol 13(suppl 5):149, 2002.
43. Smit EF, Mattson K, von Pawel J, et al: Alimta (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003.
44. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin J Clin Oncol 17:3009-3016, 1999.
45. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544, 2002.
46. Adjei AA, Erlichman C, Sloan JA, et al: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000.
47. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
48. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 (abstract 7019). Proc Am Soc Clin Oncol 23: 2004.
49. Winton TL, Livingston R, Johnson D, et al: A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 (abstract 7018). Proc Am Soc Clin Oncol 23:2004.
50. Vokes E, Szeto L, Mauer A, et al: A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-smallcell lung cancer or esophageal cancer (abstract #O-89). Lung Cancer 41(suppl 2):S89, 2003.